Search

Displaying results 1091 - 1100 of 4575 in total
  1. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  2. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.

  3. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    [L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.

  4. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].

  5. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity. … [A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and

  6. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    [L57979,L57980] It retains activity against many extended-spectrum beta-lactamase producers but not against organisms producing serine or metallo-carbapenemases. … [L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary

  7. Drug

    Methyldopa

    go.drugbank.com/drugs/DB00968
    ApprovedInvestigational

    Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].

  8. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.

  9. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371] … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  10. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]